Evidence map›Paper›PMID 36361964›Full record

ArticleInternational journal of molecular sciences2022

Th2 Cytokines (Interleukin-5 and -9) Polymorphism Affects the Response to Anti-TNF Treatment in Polish Patients with Ankylosing Spondylitis.

Sylwia Biały, Milena Iwaszko, Jerzy Świerkot, Bartosz Bugaj, Katarzyna Kolossa, Sławomir Jeka, Katarzyna Bogunia-Kubik

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Environmental and Genetic Determinants of Ankylosing Spondylitis.International journal of molecular sciences · 2024
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Sylwia BiałyLaboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.ORCID 0000-0003-1222-4231
Milena IwaszkoLaboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
Jerzy ŚwierkotDepartment of Rheumatology and Internal Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Bartosz BugajDepartment of Rheumatology and Internal Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Katarzyna KolossaDepartment of Rheumatology and Connective Tissue Diseases, Jan Biziel University Hospital No. 2, 85-268 Bydgoszcz, Poland.
Sławomir JekaDepartment of Rheumatology and Connective Tissue Diseases, Jan Biziel University Hospital No. 2, 85-268 Bydgoszcz, Poland.
Katarzyna Bogunia-KubikLaboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
Ludwik Hirszfeld Institute of Immunology and Experimental Therapy · PLWroclaw Medical University · PLJan Biziel University Hospital No. 2 in BydgoszczNicolaus Copernicus University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ankylosing spondylitis (AS) is an inflammatory disease that belongs to the spondyloarthritis family. IL-5 and IL-9 belong to the group of Th2 cytokines of anti-inflammatory nature. Polymorphisms in their coding genes have been so far associated with various inflammatory diseases, but there are no reports regarding their involvement in AS pathogenesis to date. The purpose of the study was to investigate relationships between IL5 and IL9 genetic variants with AS susceptibility, clinical parameters as well as response to therapy with TNF inhibitors. In total 170 patients receiving anti-TNF therapy and 218 healthy controls were enrolled in the study. The genotyping of IL5 rs2069812 (A > G) and IL9 rs2069885 (G > A) single nucleotide polymorphisms was performed using the Real-Time PCR method based on LightSNiP kits assays. The present study demonstrated significant relationships between IL5 rs2069812 and IL9 rs2069885 polymorphisms and response to anti-TNF therapy. Presence of the IL5 rs2069812 A allele in patients positively correlated with better response to treatment (p = 0.022). With regard to IL9 rs2069885, patients carrying the A allele displayed better outcomes in anti-TNF therapy (p = 0.046). In addition, IL5 rs2069812 A and IL9 rs2069885 A alleles were associated with lower CRP and VAS values. The obtained results may indicate a significant role for IL-5 and IL-9 in the course of AS and response to anti-TNF therapy.

Indexed as

Interleukin-5Interleukin-9Spondylitis, AnkylosingTumor Necrosis Factor InhibitorsCytokinesHumansPolandPolymorphism, Single NucleotideCytokinesInterleukin-5Interleukin-9Tumor Necrosis Factor Inhibitorsankylosing spondylitisanti-TNFIL5IL9interleukin 5interleukin 9SNP

Identifiers

PMID36361964
PMCPMC9657232
OpenAlexW4307940875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.